Peptides and the Future of Medicine

By Dr. Sofía Swatt, PhD

Disclaimer: None of the following is meant to be taken as medical advice.

Why I believe peptide therapy represents one of the most important advancements in modern medicine.

I believe the next era of medicine will be less about forcing every body through the same biochemical pathway and more about delivering the right signal at the right time.

That is what makes peptides so compelling.

Peptides are short chains of amino acids that function throughout the body as highly specific biological messengers. Hormones, growth factors, neurotransmitters, immune signals, and tissue-repair signals all rely on peptide communication. In simple terms, peptides help cells understand what to do, when to do it, and how strongly to respond.

This is not fringe science. Insulin is a peptide. Oxytocin and vasopressin are peptides. GLPs, including semaglutide, are engineered peptide analogues. GnRH analogues, somatostatin analogues, and other peptide-based drugs are already used across endocrinology, oncology, reproductive medicine, metabolic care, and rare-disease treatment. A 2025 review reported nearly 100 approved peptide drugs worldwide, with many more moving through clinical development (Xiao et al.).

To me, peptides represent a rapidly advancing pharmaceutical platform with the potential to make medicine more precise and much more personalized.

What makes peptides different than convention medication

Conventional medications are essential and often lifesaving. Many small-molecule drugs work by inhibiting an enzyme, blocking a receptor, altering a transporter, or suppressing a biochemical pathway. That may be exactly what is needed in an acute or pathological state, but some compounds can also interact with secondary targets and create effects beyond the intended pathway.

Therapeutic peptides often approach physiology differently. Many are designed to resemble, amplify, modify, or compete with signaling molecules the body already uses. Because peptide-receptor interactions can have high affinity and specificity, they may allow a more intentional biological signal than some traditional small molecules (Wang et al.; Xiao et al.).

The important distinction is not “natural peptides” versus “synthetic medications.” Peptides used therapeutically are medications, and they can be powerful. Some activate receptors; others block them. Some replace a missing signal, while others alter the intensity or duration of an existing one. Insulin can save a life, but an inappropriate dose can also be dangerous.

My philosophy is centered around accuracy: peptide therapeutics often give us an opportunity to work through the body’s existing signaling architecture instead of altering multiple unrelated targets. That does not automatically make every peptide safer or more appropriate. It makes the modality scientifically fascinating.

The history of peptides

Therapeutic peptides have been part of modern medicine for more than a century. The clinical success of insulin after its introduction in 1922, followed by the mid-century synthesis of oxytocin and vasopressin and the advent of solid-phase peptide synthesis, established peptides as a credible therapeutic class. Against this scientific backdrop, Vladimir Khavinson began investigating short, organ-specific bioregulatory peptides in the Soviet Union during the 1970s (Wang et al.; Xiao et al.; Rattan).

The modern story of peptide bioregulation began not in a wellness clinic, but in Soviet military and radiation medicine. In the 1970s and 1980s, physician-scientist Vladimir Khavinson helped establish a laboratory at the Kirov Military Medical Academy to develop compounds that could increase resilience to extreme physiological stressors, including anticipated atomic exposure. After the Chernobyl catastrophe, Khavinson reported administering the thymus-derived peptide complex Thymalin to radiation-exposed patients with profound immune suppression and observing restoration of T-cell activity (Rattan 3–6).

The earlier experimental findings were striking. In rats exposed to a single 400-rad X-ray dose, the pineal peptide complex Epithalamin was associated with a 2.7-fold reduction in malignant tumors, while Thymalin was associated with a 1.9-fold reduction. The investigators proposed that the effect involved restoration of radiation-disrupted hormonal, metabolic, and immune regulation rather than nonspecific immune stimulation (Anisimov et al. 80–82). This work helped establish Khavinson’s central concept: organ-specific peptides may act as regulatory signals that help damaged or depleted systems recover their normal patterns of cellular communication. These findings were extraordinary, yet were not published due to to current randomized-trial standards.

The foundations come first

Peptides do not create health from nothing. They deliver information—but the body still needs the raw materials and physiological capacity to act on that information.

If a peptide signals tissue repair, the body still requires adequate protein, amino acids, micronutrients, oxygenation, circulation, and restorative sleep. If an intervention influences growth-hormone or metabolic signaling, insulin sensitivity, glucose regulation, thyroid status, recovery capacity, and caloric adequacy still matter. If a GLP-1 therapy reduces appetite, protein intake, resistance training, gastrointestinal function, hydration, and micronutrient status become even more important.

A signal cannot compensate indefinitely for an under-resourced system.

Similarly, more signaling is not always better signaling. Before I consider a peptide strategy, I look at the terrain. Peptides may accelerate a well-designed plan, but they should not be used to bypass the fundamentals.

The goal is to build the physiological conditions in which an appropriate peptide has the best chance of producing a meaningful, measurable response.

I believe peptides will become a major part of the future of medicine because they move us toward a more nuanced therapeutic question. Instead of asking only, “How do we suppress this symptom?” we can begin asking, “What signal is missing, distorted, excessive, or arriving at the wrong time?”

That shift from generalized biochemical control toward targeted biological communication…is profound.

But peptides are not magic, and they are not a substitute for the foundations of health. Their greatest potential appears when advanced therapeutics are layered intelligently onto a healthful diet and lifestyle.

The future of medicine will not be peptides alone. It will be the ability to combine with innovations in modern medicine, precise testing, and individualized problem solving into one coherent strategy.

That is the future I want to help build.

Works Cited

Anisimov, V. N., et al. “Effect of Polypeptide Factors of the Thymus and Epiphysis on Radiation Carcinogenesis.” Bulletin of Experimental Biology and Medicine, vol. 94, no. 7, 1982, pp. 80–82.

Domina, E. A. “Chornobyl Catastrophe: Cytogenetic Effects of Low Dose Ionizing Radiation and Their Modification.” Experimental Oncology, vol. 38, no. 4, 2016, pp. 219–23.

Rattan, Suresh I. S. “‘I Think That the Small Peptides Are the Best for Healthy Ageing…’: An Interview with Vladimir Khavinson.” Biogerontology, vol. 14, no. 1, 2013, pp. 1–8.

U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.” FDA, accessed 30 July 2026.

Wang, Lei, et al. “Therapeutic Peptides: Current Applications and Future Directions.” Signal Transduction and Targeted Therapy, vol. 7, article 48, 2022, doi:10.1038/s41392-022-00904-4.

Xiao, Wenjing, et al. “Advance in Peptide-Based Drug Development: Delivery Platforms, Therapeutics and Vaccines.” Signal Transduction and Targeted Therapy, vol. 10, article 74, 2025, doi:10.1038/s41392-024-02107-5.